Navigation Links
Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
Date:8/6/2008

chnology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Eric Rosenberg

Cell: +972-54-566-7713

Office: +972-2-566-0001

Email: eric@oramed.com

Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-467-6950

Office: +972-2-589-2003

Email: matthew@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
3. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
7. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
8. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
9. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
10. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
11. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008).../- Simcere,Pharmaceutical G...plier of,branded generic pharmaceuticals and manuf...t Endu (also known as Endostar) in China,announce...udy., At the request of the SFDA, Simcere initiat...he safety and therapeutic efficacy of Endu, a modi...
(Date:9/3/2008)...sults from chronically infected Hepatitis C,patien...ned earlier in 2008, - Study is the first to sho... antiviral effect of therapeutic Hepatitis C vacci... move into a second generation, vaccine formulate... TLR activation, VI...
(Date:9/3/2008)...NEVA, Sept. 3 /- Artelis SA and,Selex... monoclonal antibody,production with the achieveme...ter. This record level was accomplished by applyin...erformance stable Selexis CHO,production cell line...at,Selexis SA using their proprietary Selexis Gene...
(Date:9/3/2008)...Multaq(R) (dronedarone) decreased the risk of,stro...trial flutter already adequately trea... Sept. 3 /- The results of ...udy were presented today at,the clinical trial upd...congress 2008, in Munich, Germany. Previous result...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 1Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 2Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 1Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 2Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 1Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 1HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 3
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...tem reserachers have identified a key receptor tha...e treatment of acute respiratory distress syndrome... a life-threatening condition. The receptor is s...ht, smell and taste (G-protein coupled receptors) ...
...doss urged the Prime Minister Mr. Man Mohan Singh ... smoking in the films and television. // With the ...ing failing to reach consensus on modalities for i...ss, the minister approached Prime Minister Manmoha...
...rchers might be able to isolates molecule that wou...ory.// The revolutionary study has been done indep...Children's Hospital Boston and they have identifie... how neurons change as a result of individual expe...
...he Bihar government on Wednesday for neglecting th...hief Minister of Bihar Mr. Nitish Kumar gave the n...which was carried out with immediate effect. Last...issed three medical officers and initiated departm...
Other Medicine News:
PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts.
Velocity works cooperatively with LabSofts LabNet LIS, allowing the convenience of 24-hour access to information from satellite lab locations, hospitals, physician offices and even homes.
...eld (130" x 85") allows the surgeon to view the pa...hile remaining in the sterile field. , ,Electroca...ling cords while maintaining longer cord length st...large particle screen accommodates the larger inci...
The Bohn™ Extremity Drape is economically sound - this single extremity drape replaces two large antimicrobial impregnated "Vi-Drapes" ...the traditional "shower curtain"...and your current "ex
Medicine Products: